Navidea Biopharmaceuticals, Inc. (NASDAQ:NAVB) has been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Analysts have set a twelve-month consensus target price of $2.50 for the company and are forecasting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Navidea Biopharmaceuticals an industry rank of 91 out of 255 based on the ratings given to related companies.

Separately, HC Wainwright restated a “buy” rating on shares of Navidea Biopharmaceuticals in a report on Friday, November 22nd.

Shares of NAVB opened at $0.87 on Friday. Navidea Biopharmaceuticals has a 1 year low of $0.49 and a 1 year high of $4.20.

Navidea Biopharmaceuticals (NASDAQ:NAVB) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter. The company had revenue of $0.24 million for the quarter.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages.

Further Reading: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on Navidea Biopharmaceuticals (NAVB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.